The joint work will develop artificial intelligence (AI) models to drive diagnosis and help to quantify diagnosis on a case-by-case basis.

The Boston and Shanghai-based AI teams for United Imaging will be collaborating with Massachusetts General Hospital to fight COVID using the latest advances in intelligence.

The two powerhouses of medicine and research will work together, combining their expertise in medical imaging and artificial intelligence to deploy something entirely new.

The investment seeks to use cutting edge technology in cross-modality research and development to address the entire experience of patients. The joint research collaboration will focus on bringing a new level of what some are calling “augmented intelligence” to fight the global pandemic.

Current standards focus on CT scans to identify positive cases of COVID, but these are still in the realm of traditional X-Ray diagnosis. The collaborators will use one of the largest collections of CT images to develop training programs for AI-driven diagnosis tools.

They’ll be developing AI models to drive diagnosis, testing severity, and helping to quantify diagnosis case by case. These things will also help in other potential use cases, helping streamline diagnosis and inquiry.

United Imaging is a global leader in advanced medical imaging, winning multiple awards and recognition over the years for its work in AI-driven research and development.

MGH’s artificial intelligence surgery lab is also one of recognition, building on the experience and expertise of both surgeons and artificial intelligence experts. This partnership will not only unlock better, broader diagnostics for our current issues with the pandemic disruption. It could also have far-reaching effects at the intersection of medicine and data.

As the world battles the disruption left behind by COVID, this collaboration could be a new chapter in patient care and diagnosis. Artificial intelligence won’t replace the expertise of doctors and radiologists, but it can help find deeper insights and patterns for diagnosis. It comes on the tail of a long-recognized need for better data analysis and cutting-edge tech within healthcare.

The results of the partnership and all algorithms developed from their research will remain public for the good of further medical advancement. The research will lead to other avenues and could be the first big step in a cohesive effort to assess, treat, and research further pandemics and public health matters.

DreaMed Diabetes, an AI-based remote diabetes solution, is to be made available in clinics across the US, with a particular focus on rural communities.

The new tool, which is the first of its kind to be approved by the FDA, is cloud-based and uses AI to monitor glucose levels as well as lifestyle habits, providing clinicians with an analysis of this patients data. Its aim is to enable clinicians to treat patients remotely, by providing a fast, accurate and thorough analysis. Research found its insulin management to be just as effective as treatment programmes managed by humans.

The Center for Disease Control and Prevention (CDC) estimates that 10% of the USA’s adult population, or 34 million people have diabetes. The USA’s healthcare system is under pressure due to the pandemic, and additionally diabetes has proven to be a factor in increasing the risk of mortality in patients with Covid-19. As a result tech companies are stepping with telehealth solutions that can ease the burden on healthcare staff.

DreaMed will now be available in clinics across the country, including Lucile Packard Children’s Hospital Stanford, the Billings Clinic in Montana, Hassenfeld Children’s Hospital at NYU Langone and University of Florida Health.

These clinics will implement DreaMed’s programme into their existing protocols. It will provide patients with personalised optimisation of their insulin therapy management. Recommendations are based on its AI-driven analyses of information derived from glucometers, insulin pumps, and event-oriented data.

“It’s wonderful to see our remote diabetes solution being rolled out in so many clinics across the country, particularly at a time when people need it most” Eldad Postan-Koren, COO of DreaMed Diabetes said.

“Our mission is, and always will be, to provide people with diabetes and their health care professionals with a reliable, insulin-therapy management tool that enables the best care possible wherever they are.”

DreaMed Diabetes, headquartered in Tel Aviv, was founded in 2014 as a spin-off of the DREAM International Consortium, to commercialise the insulin control technology behind the Glucositter .

Siemens Healthineers is debuting its new fluoroscopy system, the Luminos Lotus Max, at the annual French JFR 2020. The system offers industry-leading technology in radiography and fluoroscopy. “Combining these state-of-the-art technologies poses one major challenge: ensuring efficient workflows and high system utilization. With our new device, healthcare professionals now benefit from a new level of integration for ‘uninterrupted flow‘ in radiographic and fluoroscopic exams. It’s all on one system and in one room,” says Carsten Bertram, Head of Business Line X-ray Products.

The remote-controlled Luminos Lotus Max system offers tremendous versatility in clinical examinations, as it combines radiographic and fluoroscopic imaging with orthopedic studies such as long leg or spinal examinations and basic interventions. Because these capabilities are highly integrated, users can quickly switch between the different imaging modalities. The Luminos Lotus Max also features a high degree of automation aimed at ensuring ease of use and patient safety. This automation helps technicians apply the optimal radiation dose for each patient and examination type without compromising clinical results. The device automatically encrypts all images and patient data. Combined with regular software updates to prevent new risks and an elaborate role-based access control, this ensures that the highest cybersecurity standards are met.

1 LUMINOS Lotus Max is not yet commercially available in all countries. The products and/or features mentioned here are not commercially available in all countries and/or for all modalities. Their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

About Siemens Healthineers AG

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.

Medtronic plc , the global leader in medical technology, announced it has received U.S. FDA approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ DES. The Resolute Onyx DES is the first-and-only DES in the U.S. that has been proven safe and effective utilizing a one-month regimen of DAPT – the combination of aspirin and an anti-clotting medication – following a percutaneous coronary intervention (PCI) in patients at high bleeding risk.

Patients that are at risk for high bleeding include older patients, those with history of bleeding, or those on oral blood-thinning drugs, and account for up to 40 percent of PCI patients1. Clinical studies have demonstrated that Resolute Onyx DES and its biocompatible polymer and stent design promote fast vessel healing and is well-suited for patients who may benefit from a DAPT duration as short as one month2.

“It is so rewarding to see the efforts of those involved in examining the safety and efficacy of one-month of DAPT following PCI – the coordinators, investigators and most importantly the Onyx One Clear patient participants – come to fruition with this new high bleeding risk indication for the Resolute Onyx drug eluting stent,” said Ajay Kirtane, M.D., professor of medicine at Columbia University Vagelos College of Physicians and Surgeons and principal investigator for the Onyx One Clear study. “It is remarkable how the combination of technology innovation, in conjunction with the generation of clinical evidence, has informed our understanding that shorter durations of DAPT may in fact be safe in appropriately selected patients treated with Resolute Onyx DES.”

Using a broad criteria for HBR, the approval is based on results from the Onyx ONE Clear Study that evaluated approximately 1500 complex HBR patients on one-month DAPT treated with Resolute Onyx. At one year, the study met its primary endpoint of cardiac death or myocardial infarction and showed Resolute Onyx to be safe and effective in HBR patients on one-month DAPT. Results from the study were shared virtually in March at the American College of Cardiology together with the World Congress of Cardiology Scientific Sessions (ACC.20/WCC). The Onyx ONE Clear study, coupled with the Onyx ONE Global study, make up the Onyx ONE Month DAPT Program that supports the advancement of DAPT evidence, initiated by physicians and Medtronic.

“The journey leading to an HBR indication has included years of rigorous clinical evaluation with more than 22,000 complex patients studied,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. “We’re excited to realize our goal of providing physicians with more robust data and a supporting indication to inform treatment decisions for HBR patients, who may be suitable for a one-month course of DAPT.”

In May, the Resolute Onyx was the first DES to receive CE Mark for a one-month DAPT indication for patients at high bleeding risk in Europe.

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Amgen announced a new partnership with two NHS organisations, the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will help tackle the ‘silent killer’ of high cholesterol across the North West Coast of England – an area heavily impacted by heart attacks, strokes, and premature deaths due to cardiovascular disease (CVD).

‘Control Cholesterol: Collaborating to Reduce Risk’ is an innovative two-year programme adopting a quality management approach to improve health outcomes for people at high risk of a CVD event, due to raised cholesterol. It is part of a global Amgen initiative seeking to improve human health by not only treating diseases after they strike, but by helping to predict and prevent illnesses before they occur. The UK programme is one of the largest ‘predict and prevent’ commitments by Amgen outside of the United States.

Together with its NHS partners, Amgen will be working with primary care networks, clinical commissioning groups, and GP practices to develop scalable, evidence-based solutions that deliver cost efficiencies and capacity savings. Through earlier interventions, the collaboration will support people most at risk of a CVD event, improve care to help them remain as healthy as possible, and potentially prevent them from suffering a life-threatening heart attack or stroke. Improved pathways for these patients in primary care will ensure they receive appropriate advice and treatment outside the hospital setting. This will help preserve hospital capacity to enable the NHS to deal with other acute healthcare challenges, such as COVID-19 and the winter flu season, as well as supporting the NHS to deliver its Long Term Plan vision1.

Nationally, approximately 6.1 million2 people are living with heart and circulatory diseases, which account for more than a quarter2 (27%) of all deaths in England, costing the NHS an estimated £7.4 billion each year2. Cardiovascular disease is also the largest cause of premature death in deprived areas3. These statistics demonstrate the importance of innovative collaboration between the NHS, academia, and the biotechnology industry to find new and sustainable solutions that improve lives and can benefit the health system over the long term.

Through ‘Control Cholesterol: Collaborating to Reduce Risk’, more than 300,0004,5 people in the North West of England with potentially high cholesterol levels, will benefit from improved CVD care and cholesterol management. This includes approximately 150,0004,5 who are at very high risk of having a heart attack or stroke.

Using a predictive software model developed by Imperial College Health Partners, ‘Control Cholesterol: Collaborating to Reduce Risk’ will enable health organisations to identify gaps in cholesterol management, understand the number of people at risk of CVD, and model the potential health outcomes and cost savings of improving care.

Implementing the model in the North West region – an area where early deaths from cardiovascular disease before the age of 75 are the highest6 in England and 20%6 higher than the national average – will provide invaluable insights that inform how Amgen and its NHS partners can work together to develop new models of care for people with raised cholesterol.

Dr Tony Patrikios, executive medical director at Amgen UK and Ireland, said: “As the front line of the NHS, primary care plays a critical role in identifying patients at high risk of suffering cardiovascular events, and ensuring they are appropriately treated or referred on for timely treatment and optimal management. This collaboration brings together the collective scientific expertise, clinical experience, and deep understanding of cardiovascular disease of Amgen and our NHS partners, to provide a meaningful contribution to the NHS in achieving its Long Term Plan ambition of preventing up to 150,0007 avoidable cardiovascular events over the next 10 years.”

Dr Phil Jennings, medical director of the North West Coast Innovation Agency, said: “We have previously led successful programmes to tackle the risk factors for cardiovascular disease, atrial fibrillation and high blood pressure. We’re very proud of our record in this area and the collaboration with Amgen will help us continue in the same direction by identifying people with raised cholesterol, which is a major cause of heart attacks and strokes. There’s no question that tackling cardiovascular disease in our region is a very high priority. Our hope is that the programme will quickly identify people who are most at risk and start to improve outcomes quickly.”

Dr. Jonty Heaversedge, Clinical Director at Imperial College Health Partners (ICHP) said: “At ICHP we have considerable experience in developing and delivering effective tools to identify and treat patients with atrial fibrillation and to help reduce the variation in their care. The NHS is putting increasing emphasis on preventative rather than reactive treatment options and the predictive software model that we are developing as part of the collaboration with Amgen supports this prevention strategy to avoid more serious, and potentially more costly, health problems and treatments associated with cardiovascular disease. This is not only better for the patient but for the wider system too.”

High-risk patient groups in this region are in an even more critical position as a result of the COVID-19 pandemic. The impact of coronavirus on the cardiovascular system has increased the need for quality management interventions that can reduce cardiovascular morbidity and mortality, with people suffering from cardiac disease comprising almost 30%8 of COVID-19 hospitalisations. The COVID-19 pandemic has acted as a catalyst for accelerating change, with the NHS responding by adopting new and innovative ways of treating patients. ‘Control Cholesterol: Collaborating to Reduce Risk’ is another opportunity to harness this innovation and provide patient-centred care in ways that move more services out of hospital and into the community.

About NHS North West Coast Innovation Agency
The Innovation Agency is an Academic Health Science Network, one of 15 AHSNs in England operating as the innovation arm of the NHS as part of the national AHSN Network. The Innovation Agency covers the North West Coast – Cheshire, Merseyside, South Cumbria and Lancashire, serving a population of just over four million residents. The Innovation Agency’s role is to spread innovations at pace and scale, helping facilitate change across whole health and social care economies, to improve health, drive down the cost of care, and stimulate economic growth.

About Imperial College Health Partners
Imperial College Health Partners (ICHP) is a partnership organisation bringing together NHS providers of healthcare services, clinical commissioning groups and leading universities across North West London. We are also the designated Academic Health Science Network (AHSN) for North West London as part of the national AHSN Network. We were created by the NHS to support complex change across the health and care sector – innovating and collaborating for a healthier population.

About Amgen in the UK and Ireland
Amgen is committed to the relentless pursuit of breakthroughs and making a sustainable contribution to healthcare. A biotechnology pioneer since 1980, Amgen serves patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.

Amgen develops innovative medicines in cancer and long-term conditions by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. As one of the most forward-thinking and innovative biotech companies, Amgen’s growing portfolio of medicines tackle some of the biggest healthcare burdens facing society today.

The UK and Ireland is one of Amgen’s largest sites outside of the company headquarters in California and is a European hub for research and development. More than 500 people at Amgen in the UK and Ireland contribute to the journey that turns molecules into medicines, and in 2019 approximately 253,000 UK and Irish patients were treated with Amgen medicines.

Phreesia, the nation’s leading patient intake platform, is pleased to announce that it has acquired two web-based workflow applications co-developed by Geisinger, a large health system based in Danville, Pa., and Merck, known as MSD outside of the USA and Canada. The newly acquired applications are designed to help improve patient communication and care delivery.

The Family Caregiver application facilitates two-way communications and coordination of care for oncology patients and their caregivers. The other application, MedTrue™, integrates different medication data sources to assist with medication reconciliation and adherence, resulting in a patient- and healthcare team-verified medication list.

“Phreesia supports technologies that engage patients in their care and improve health outcomes,” said Phreesia’s CEO Chaim Indig. “Acquiring these applications that were co-developed by Merck and Geisinger helps support our mission of creating a better healthcare experience.”

The applications are embedded directly within the electronic health record (EHR) and the healthcare provider’s workflow to enhance the use of clinical and patient-reported data during patient appointments. Patients can access both applications from the convenience of home and the Family Caregiver Application is also available to family caregivers.

“At Geisinger’s Steele Institute for Health Innovation, our mission is to build solutions that improve health, the patient experience, care delivery and affordability,” said Karen Murphy, Ph.D., Executive Vice President and Chief Innovation Officer at Geisinger. “Seeing the opportunity for the Family Caregiver and MedTrue applications to fulfill this mission is a source of great pride.”

“This agreement represents the culmination of a long and productive collaboration between the Merck and Geisinger team. Merck is excited that our collaboration with Geisinger yielded these two applications that will be incorporated into Phreesia’s offerings,” said Kathryn Hayward, Vice President of Strategy and Commercial Operations – U.S. Market, Merck.

ABOUT PHREESIA

Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, consistent experience, while enabling healthcare organizations to enhance clinical care and drive efficiency.

About Geisinger

Geisinger is committed to making better health easier for the more than 1.5 million consumers it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 13 hospital campuses, a 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With 32,000 employees and 1,800 employed physicians, Geisinger boosts its hometown economies in Pennsylvania and New Jersey by billions of dollars annually.

Today, four revenue cycle management services and technology organizations have merged together as a newly-formed entity CorroHealth. TrustHCS, Visionary RCM, T-System, and RevCycle+ have joined forces to provide a greater breadth of reimbursement cycle, risk adjustment, and quality solutions to health systems and payers.

What is CorroHealth?

CorroHealth—driven by helping clients navigate regulatory and compliance complexities, ease physician burdens and improve financial outcomes—emerges at a time when financial health is particularly important for health systems and payers. CorroHealth combines the industry-leading domestic middle revenue cycle group of TrustHCS, with the full-service global delivery model of Visionary RCM, the emergency documentation technology solutions of T-System, and the advanced coding solutions of RevCycle+.

“We knew health systems and plans would have a growing need for our solutions, so we worked hard and found a way to bring all 4,000 employees together as one company, united by our core. It’s been pretty amazing to see this joint venture come together at such a time as this,” said CorroHealth CEO Patrick Leonard.

The four legacy company names will remain through the end of 2020 with a final move to the CorroHealth name across all companies beginning January 1, 2021.

Global investment firm The Carlyle Group owns a majority stake in CorroHealth, with Cannae Holdings, Inc., Sanaka Group, and affiliates of TripleTree Holdings also serving as investors.

Revel and NovuHealth, two of the nation’s leading healthcare consumer engagement, communications and technology companies, announced a merger of the companies effective immediately. The merger establishes Revel and NovuHealth as the largest technology company focused on member engagement for healthcare’s most trusted organizations.

The merger establishes Revel and NovuHealth as the largest technology company focused on member engagement for healthcare’s most trusted organizations and delivers a next-generation SaaS platform that creates omnichannel personalization at scale for healthcare. Together, Revel and NovuHealth work with more than 50 healthcare organizations, including seven of the top 10 largest health insurers in the United States representing more than 65 percent of all members in government programs such as Medicare and Medicaid.

Over the course of the next few months, the Revel and NovuHealth teams will be working to merge their sales and marketing operations, customer experience, operations and product teams. The new company will continue to operate in growth mode and expects to add professional talent through the balance of the year. The company will reveal a new brand for the combined enterprise in the new year.

As part of the merger, NovuHealth CEO Steve Wigginton will serve as CEO, while Revel CEO Jeff Fritz will transition to an advisor to the CEO and the board of directors of the merged company.

“This merger creates a dream team of experts in consumer marketing, behavioral science, healthcare regulatory expertise, data science and technology,” said Jeff Fritz, CEO of Revel. “This is a rare opportunity to connect the complementary nature of the Revel and NovuHealth platforms to create personalization at scale for the most trusted healthcare organizations. The result is a platform designed to reach the full spectrum of members including the hardest to reach, noncompliant consumers who are the toughest to motivate to take healthy actions,” Fritz said.